Development and Pharmacokinetics Study of Antifungal Peptide Nanoliposomes by Liquid Chromatography-tandem Mass Spectrometry

Author(s): Shuoye Yang*

Journal Name: Current Pharmaceutical Analysis

Volume 15 , Issue 4 , 2019


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: The therapeutic ability and application of antifungal peptide (APs) are limited by their physico-chemical and biological properties, the nano-liposomal encapsulation would improve the in vivo circulation and stability.

Objective: To develop a long-circulating liposomal delivery systems encapsulated APs-CGA-N12 with PEGylated lipids and cholesterol, and investigated through in vivo pharmacokinetics.

Methods: The liposomes were prepared and characterized, a rapid and simple liquid chromatographytandem mass spectrometry (LC-MS/MS) assay was developed for the determination of antifungal peptide in vivo, the pharmacokinetic characteristics of APs liposomes were evaluated in rats.

Results: Liposomes had a large, unilamellar structure, particle size and Zeta potential ranged from 160 to 185 nm and -0.55 to 1.1 mV, respectively. The results indicated that the plasma concentration of peptides in reference solutions rapidly declined after intravenous administration, whereas the liposomeencapsulated ones showed slower elimination. The AUC(0-∞) was increased by 3.0-fold in liposomes in comparison with standard solution (20 mg·kg-1), the half-life (T1/2) was 1.6- and 1.5-fold higher compared to the reference groups of 20 and 40 mg·kg-1, respectively.

Conclusion: Therefore, it could be concluded that liposomal encapsulation effectively improved the bioavailability and pharmacokinetic property of antifungal peptides.

Keywords: Antifungal peptide, liposomes, pharmacokinetics, in vivo, LC-MS/MS, protein drugs.

[1]
Hrubyand, V.J.; Balse, P.M. Conformational and topographical considerations in designing agonist peptidomimetics from peptide leads. Curr. Med. Chem., 2000, 7, 945-970.
[2]
Gentilucci, L.; De Marco, R.; Cerisoli, L. Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization. Curr. Pharm. Des., 2010, 16, 3185-3203.
[3]
Wan, H.; Lee, K.S.; Kim, B.Y.; Yuan, M.; Zhan, S.; Lu, Y.; You, H.; Li, J.; Jin, B.R. Developmental regulation and antifungal activity of a growth-blocking peptide from the beet armyworm Spodoptera exigua. DCI, 2013, 41, 240-247.
[4]
Ron-Doitch, S.; Sawodny, B.; Kuhbacher, A.; David, M.M.; Samanta, A.; Phopase, J.; Burger-Kentischer, A.; Griffith, M.; Golomb, G.; Rupp, S. Reduced cytotoxicity and enhanced bioactivity of cationic antimicrobial peptides liposomes in cell cultures and 3D epidermis model against HSV. J. Control. Release, 2016, 229, 163-171.
[5]
Lee, J.; Huang, W.; Broering, J.M.; Barron, A.E.; Seo, J. Prostate tumor specific peptide-peptoid hybrid prodrugs. Bioorg. Med. Chem. Lett., 2015, 25, 2849-2852.
[6]
Volkov, G.L.; Havryliuk, S.P.; Krasnobryzha, I.M. Havryliuk. O.S. The protein/peptide direct virus inactivation during chromatographic process: Developing approaches. Appl. Biochem. Biotechnol., 2017, 181(1), 233-249.
[7]
Jung, S.Y.; Kang, E.Y.; Choi, Y.J.; Chun, I.K.; Lee, B.K.; Gwak, H.S. Formulation and evaluation of ubidecarenone transdermal delivery systems. Drug Dev. Ind. Pharm., 2009, 35, 1029-1034.
[8]
Werle, M.; Hironaka, K.; Takeuchi, H.; Hoyer, H. Development and in vitro characterization of liposomes coated with thiolated poly(acrylic acid) for oral drug delivery. Drug Dev. Ind. Pharm., 2009, 35, 209-215.
[9]
Matougui, N.; Boge, L.; Groo, A.C.; Umerska, A.; Ringstad, L.; Bysell, H.; Saulnier, P. Lipid-based nanoformulations for peptide delivery. Int. J. Pharm., 2016, 502, 80-97.
[10]
Kuang, Y.; Liu, J.; Liu, Z.; Zhuo, R. Cholesterol-based anionic long-circulating cisplatin liposomes with reduced renal toxicity. Biomaterials, 2012, 33, 1596-1606.
[11]
Yang, S.; Chen, J.; Zhao, D.; Han, D.; Chen, X. Comparative study on preparative methods of DC-Chol/DOPE liposomes and formulation optimization by determining encapsulation efficiency. Int. J. Pharm., 2012, 434, 155-160.
[12]
Hu, Y.; Jin, Y.; Xia, Y. The characterization of cationic fusogenic liposomes mediated antisense oligonucleotides into HeLa cells. Drug Dev. Ind. Pharm., 2004, 30, 135-141.
[13]
Kajiwara, E.; Kawano, K.; Hattori, Y.; Fukushima, M.; Hayashi, K.; Maitani, Y. Long-circulating liposome-encapsulated ganciclovir enhances the efficacy of HSV-TK suicide gene therapy. J. Control. Release, 2007, 120, 104-110.
[14]
Li, R.; Lu, Z.; Sun, Y.; Chen, S.; Yi, Y.; Zhang, H.; Yang, S.; Yu, G.; Huang, L.G. Li. C. Molecular Design, Structural Analysis and Antifungal Activity of Derivatives of Peptide CGA-N46. Interdiscip. Sci. Comput. Life Sci, 2016, 8, 319-326.
[15]
Yang, S.; Talbi, A.; Wang, X.; Song, H.; Chen, X. Pharmacokinetics study of calf thymus DNA in rats and beagle dogs with (3)H-labeling and tracing method. J. Pharm. Biomed. Anal., 2014, 88, 60-65.
[16]
Al Souhail, Q.; Hiromasa, Y.; Rahnamaeian, M.; Giraldo, M.C.; Takahashi, D.; Valent, B.; Vilcinskas, A.; Kanost, M.R. Characterization and regulation of expression of an antifungal peptide from hemolymph of an insect, Manduca sexta. Dev. Comp. Immunol., 2016, 61, 258-268.
[17]
Faruck, M.O.; Yusof, F.; Chowdhury, S. An overview of antifungal peptides derived from insect. Peptides, 2016, 80, 80-88.
[18]
Alexander, M.S.; Kiser, M.M.; Culley, T.; Kern, J.R.; Dolan, J.W.; McChesney, J.D.; Zygmunt, J.; Bannister, S.J. Measurement of paclitaxel in biological matrices: high-throughput liquid chromatographic-tandem mass spectrometric quantification of paclitaxel and metabolites in human and dog plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2003, 785, 253-261.
[19]
Kim, S.C.; Yu, J.; Lee, J.W.; Park, E.S. Chi. S.C. Sensitive HPLC method for quantitation of paclitaxel (Genexol in biological samples with application to preclinical pharmacokinetics and biodistribution. J. Pharm. Biomed. Anal., 2005, 39, 170-176.
[20]
Guo, P.; Ma, J.; Li, S.; Gallo, J.M. Determination of paclitaxel in mouse plasma and brain tissue by liquid chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2003, 798, 79-86.
[21]
Santos, L.H.; Ramalhosa, M.J.; Ferreira, M.; Delerue-Matos, C. Development of a modified acetonitrile-based extraction procedure followed by ultra-high performance liquid chromatography-tandem mass spectrometry for the analysis of psychiatric drugs in sediments. J. Chromatogr. A, 2016, 1437, 37-48.
[22]
Wang, X.; Song, L.; Li, N.; Qiu, Z.; Zhou, S.; Li, C.; Zhao, J.; Song, H.; Chen, X. Pharmacokinetics and biodistribution study of paclitaxel liposome in Sprague-Dawley rats and Beagle dogs by liquid chromatography-tandem mass spectrometry. Drug Res., 2013, 63, 603-606.
[23]
Li, X.; Li, N.; Wang, C.; Deng, S.; Sun, X.; Zhang, W.; Gao, W.; Zhao, D.; Lu, Y.; Chen, X. Development and validation of a simple and reliable LC-MS/MS method for the determination of acetazolamide, an effective carbonic anhydrase inhibitor, in plasma and its application to a pharmacokinetic study. Drug Res., 2014, 64, 499-504.
[24]
Liuand, C.W.; Murray, J.D. The role of flavonoids in nodulation host-range specificity: An update Plants (Basel),, 2016, 5 (3), pii: E33.
[25]
Chono, S.; Suzuki, H.; Togami, K.; Morimoto, K. Efficient drug delivery to lung epithelial lining fluid by aerosolization of ciprofloxacin incorporated into PEGylated liposomes for treatment of respiratory infections. Drug Dev. Ind. Pharm., 2011, 37, 367-372.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 4
Year: 2019
Published on: 19 March, 2019
Page: [312 - 318]
Pages: 7
DOI: 10.2174/1573412914666180307155328
Price: $65

Article Metrics

PDF: 47
HTML: 1